Epithelial-to-mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity

Deli Hong, Andrew J. Fritz, Sayyed K. Zaidi, Andre J van Wijnen, Jeffrey A. Nickerson, Anthony N. Imbalzano, Jane B. Lian, Janet L. Stein, Gary S. Stein

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Breast cancer is the most common cancer in women, and accounts for ~30% of new cancer cases and 15% of cancer-related deaths. Tumor relapse and metastasis are primary factors contributing to breast cancer-related deaths. Therefore, the challenge for breast cancer treatment is to sustain remission. A driving force behind tumor relapse is breast cancer heterogeneity (both intertumor, between different patients, and intratumor, within the same tumor). Understanding breast cancer heterogeneity is necessary to develop preventive interventions and targeted therapies. A recently emerging concept is that intratumor heterogeneity is driven by cancer stem cells (CSCs) that are capable of giving rise to a multitude of different cells within a tumor. Studies have highlighted linkage of CSC formation with epithelial-to-mesenchymal transition (EMT). In this review, we summarize the current understanding of breast cancer heterogeneity, links between EMT and CSCs, regulation of EMT by Runx transcription factors, and potential therapeutic strategies targeting these processes.

Original languageEnglish (US)
JournalJournal of Cellular Physiology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Epithelial-Mesenchymal Transition
Neoplastic Stem Cells
Stem cells
Mesenchymal Stromal Cells
Tumors
Breast Neoplasms
Neoplasms
Oncology
Transcription Factors
Recurrence
Therapeutics
Neoplasm Metastasis

Keywords

  • Breast cancer
  • Cancer stem cell (CSC)
  • Epithelial-to-mesenchymal transition (EMT)
  • Tumor heterogeneity

ASJC Scopus subject areas

  • Physiology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Hong, D., Fritz, A. J., Zaidi, S. K., van Wijnen, A. J., Nickerson, J. A., Imbalzano, A. N., ... Stein, G. S. (Accepted/In press). Epithelial-to-mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity. Journal of Cellular Physiology. https://doi.org/10.1002/jcp.26847

Epithelial-to-mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity. / Hong, Deli; Fritz, Andrew J.; Zaidi, Sayyed K.; van Wijnen, Andre J; Nickerson, Jeffrey A.; Imbalzano, Anthony N.; Lian, Jane B.; Stein, Janet L.; Stein, Gary S.

In: Journal of Cellular Physiology, 01.01.2018.

Research output: Contribution to journalArticle

Hong, D, Fritz, AJ, Zaidi, SK, van Wijnen, AJ, Nickerson, JA, Imbalzano, AN, Lian, JB, Stein, JL & Stein, GS 2018, 'Epithelial-to-mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity', Journal of Cellular Physiology. https://doi.org/10.1002/jcp.26847
Hong, Deli ; Fritz, Andrew J. ; Zaidi, Sayyed K. ; van Wijnen, Andre J ; Nickerson, Jeffrey A. ; Imbalzano, Anthony N. ; Lian, Jane B. ; Stein, Janet L. ; Stein, Gary S. / Epithelial-to-mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity. In: Journal of Cellular Physiology. 2018.
@article{0c2f4b7709de4852aa0f053b7beacca4,
title = "Epithelial-to-mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity",
abstract = "Breast cancer is the most common cancer in women, and accounts for ~30{\%} of new cancer cases and 15{\%} of cancer-related deaths. Tumor relapse and metastasis are primary factors contributing to breast cancer-related deaths. Therefore, the challenge for breast cancer treatment is to sustain remission. A driving force behind tumor relapse is breast cancer heterogeneity (both intertumor, between different patients, and intratumor, within the same tumor). Understanding breast cancer heterogeneity is necessary to develop preventive interventions and targeted therapies. A recently emerging concept is that intratumor heterogeneity is driven by cancer stem cells (CSCs) that are capable of giving rise to a multitude of different cells within a tumor. Studies have highlighted linkage of CSC formation with epithelial-to-mesenchymal transition (EMT). In this review, we summarize the current understanding of breast cancer heterogeneity, links between EMT and CSCs, regulation of EMT by Runx transcription factors, and potential therapeutic strategies targeting these processes.",
keywords = "Breast cancer, Cancer stem cell (CSC), Epithelial-to-mesenchymal transition (EMT), Tumor heterogeneity",
author = "Deli Hong and Fritz, {Andrew J.} and Zaidi, {Sayyed K.} and {van Wijnen}, {Andre J} and Nickerson, {Jeffrey A.} and Imbalzano, {Anthony N.} and Lian, {Jane B.} and Stein, {Janet L.} and Stein, {Gary S.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/jcp.26847",
language = "English (US)",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Epithelial-to-mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity

AU - Hong, Deli

AU - Fritz, Andrew J.

AU - Zaidi, Sayyed K.

AU - van Wijnen, Andre J

AU - Nickerson, Jeffrey A.

AU - Imbalzano, Anthony N.

AU - Lian, Jane B.

AU - Stein, Janet L.

AU - Stein, Gary S.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Breast cancer is the most common cancer in women, and accounts for ~30% of new cancer cases and 15% of cancer-related deaths. Tumor relapse and metastasis are primary factors contributing to breast cancer-related deaths. Therefore, the challenge for breast cancer treatment is to sustain remission. A driving force behind tumor relapse is breast cancer heterogeneity (both intertumor, between different patients, and intratumor, within the same tumor). Understanding breast cancer heterogeneity is necessary to develop preventive interventions and targeted therapies. A recently emerging concept is that intratumor heterogeneity is driven by cancer stem cells (CSCs) that are capable of giving rise to a multitude of different cells within a tumor. Studies have highlighted linkage of CSC formation with epithelial-to-mesenchymal transition (EMT). In this review, we summarize the current understanding of breast cancer heterogeneity, links between EMT and CSCs, regulation of EMT by Runx transcription factors, and potential therapeutic strategies targeting these processes.

AB - Breast cancer is the most common cancer in women, and accounts for ~30% of new cancer cases and 15% of cancer-related deaths. Tumor relapse and metastasis are primary factors contributing to breast cancer-related deaths. Therefore, the challenge for breast cancer treatment is to sustain remission. A driving force behind tumor relapse is breast cancer heterogeneity (both intertumor, between different patients, and intratumor, within the same tumor). Understanding breast cancer heterogeneity is necessary to develop preventive interventions and targeted therapies. A recently emerging concept is that intratumor heterogeneity is driven by cancer stem cells (CSCs) that are capable of giving rise to a multitude of different cells within a tumor. Studies have highlighted linkage of CSC formation with epithelial-to-mesenchymal transition (EMT). In this review, we summarize the current understanding of breast cancer heterogeneity, links between EMT and CSCs, regulation of EMT by Runx transcription factors, and potential therapeutic strategies targeting these processes.

KW - Breast cancer

KW - Cancer stem cell (CSC)

KW - Epithelial-to-mesenchymal transition (EMT)

KW - Tumor heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=85050486945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050486945&partnerID=8YFLogxK

U2 - 10.1002/jcp.26847

DO - 10.1002/jcp.26847

M3 - Article

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

ER -